{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:01:55Z","timestamp":1787320915809,"version":"build-2736575974"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["403493\/2021-8 305459\/2019-8"],"award-info":[{"award-number":["403493\/2021-8 305459\/2019-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017425","name":"Pr\u00f3-Reitoria de Pesquisa e P\u00f3s-Gradua\u00e7\u00e3o, Universidade Federal do Par\u00e1","doi-asserted-by":"publisher","award":["APC"],"award-info":[{"award-number":["APC"]}],"id":[{"id":"10.13039\/100017425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Postdoctoral grant"],"award-info":[{"award-number":["Postdoctoral grant"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Chronic myeloid leukemia (CML) is caused by constitutively active fusion protein BCR-ABL1, and targeting ABL1 is a promising therapy option. Imatinib, dasatinib, and nilotinib have all been shown to work effectively in clinical trials. ABL1 mutations, particularly the T315I gate-keeper mutation, cause resistance in patients. As a result, broad-spectrum ABL1 medicines are desperately needed. In order to screen potential drugs targeting CML, mebendazole (MBZ) was subjected to the\n                    <jats:italic>in vitro<\/jats:italic>\n                    test against CML cell lines (K562 and FEPS) and computational assays. The antiproliferative effect of MBZ and the combination with tyrosine kinase inhibitors (TKIs) was tested using end-point viability assays, cell cycle distribution analysis, cell membrane, and mitochondrial dyes. By interrupting the cell cycle and causing cell death, MBZ and its combination with imatinib and dasatinib have a significant antiproliferative effect. We identified MBZ as a promising \u201cnew use\u201d drug targeting wild-type and mutant ABL1 using molecular docking. Meanwhile, we determined which residues in the allosteric site are important in ABL1 drug development. These findings may not only serve as a model for repositioning current authorized medications but may also provide ABL1-targeted anti-CML treatments a fresh lease of life.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.952250","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:31:01Z","timestamp":1661387461000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Anticancer potential of mebendazole against chronic myeloid leukemia: in silico and in vitro studies revealed new insights about the mechanism of action"],"prefix":"10.3389","volume":"13","author":[{"given":"Julio Paulino","family":"Daniel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Pantoja","family":"Mesquita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson Lucena","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Filho Noronha","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luina Benevides","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lais Lacerda Brasil","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisabete Amaral","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline de F\u00e1tima Aquino","family":"Moreira-Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geancarlo","family":"Zanatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Carvalho","family":"Montenegro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2174\/157340612800493719","article-title":"Synthesis and anticancer activity of novel benzimidazole and benzothiazole derivatives against HepG2 liver cancer cells","volume":"8","author":"Youssef","year":"2012","journal-title":"Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 tyrosine kinase complex signaling transduction: Challenges to overcome resistance in chronic myeloid leukemia","volume":"14","author":"Amarante-Mendes","year":"2022","journal-title":"Pharmaceutics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fmed.2017.00211","article-title":"Drug repurposing for the treatment of acute myeloid leukemia","volume":"4","author":"Andresen","year":"2017","journal-title":"Front. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"N15","DOI":"10.1227\/01.NEU.0000460594.93803","article-title":"Repurposing mebendazole for the treatment of medulloblastoma","volume":"76","author":"Bodhinayake","year":"2015","journal-title":"Neurosurgery"},{"key":"B5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/S11010-013-1761-0","article-title":"Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms","volume":"383","author":"Daflon-Yunes","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/CBIN.11137","article-title":"Cell death: A review of the major forms of apoptosis, necrosis and autophagy","volume":"43","author":"D\u2019Arcy","year":"2019","journal-title":"Cell. Biol. Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0091-679X(08)61707-0","article-title":"Assays of cell viability: Discrimination of cells dying by apoptosis","volume":"41","author":"Darzynkiewicz","year":"1994","journal-title":"Methods Cell. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/CAD.0B013E32835A43F1","article-title":"XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts","volume":"24","author":"Doudican","year":"2013","journal-title":"Anticancer. Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"vdaa154","DOI":"10.1093\/NOAJNL\/VDAA154","article-title":"Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: Results of a phase 1 clinical trial","volume":"3","author":"Gallia","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"B13","doi-asserted-by":"publisher","first-page":"W32","DOI":"10.1093\/NAR\/GKU293","article-title":"SwissTargetPrediction: A web server for target prediction of bioactive small molecules","volume":"42","author":"Gfeller","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E1284","DOI":"10.3390\/CANCERS11091284","article-title":"Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature","volume":"11","author":"Guerini","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2217\/fon.09.127","article-title":"New hopes from old drugs: Revisiting DNA-binding small molecules as anticancer agents","volume":"5","author":"Gurova","year":"2009","journal-title":"Future Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13039-021-00539-0","article-title":"Philadelphia chromosome positive chronic myeloid leukemia with 5q deletion at diagnosis","volume":"14","author":"Haidary","year":"2021","journal-title":"Mol. Cytogenet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/AJH.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2174\/2589977512999200821170221","article-title":"Repurposing of benzimidazole scaffolds for HER2 positive breast cancer therapy: An in-silico approach","volume":"13","author":"Jubie","year":"2021","journal-title":"Curr. drug Res. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/CAD.0B013E3283648C69","article-title":"Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines","volume":"24","author":"Kr\u00e1lov\u00e1","year":"2013","journal-title":"Anticancer. Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"16775","DOI":"10.1038\/s41598-019-53290-3","article-title":"Mebendazole for differentiation therapy of acute myeloid leukemia identified by a lineage maturation index","volume":"9","author":"Li","year":"2019","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES25061375","volume":"25","author":"Lin","year":"2020","journal-title":"A Review on Applications of Computational Methods in Drug Screening and DesignMolecules"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3390\/pharmaceutics13101604","article-title":"Kinase inhibition in relapsed\/refractory leukemia and lymphoma settings: Recent prospects into clinical investigations","volume":"13","author":"Machado","year":"2021","journal-title":"Pharmaceutics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"8981","DOI":"10.1038\/s41598-021-88433-y","article-title":"A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer","author":"Mansoori","year":"2021","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-020-00185-z","article-title":"Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: A population-based epidemiologic study","volume":"9","author":"Ning","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/S00432-013-1539-5","article-title":"Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer","volume":"139","author":"Nygren","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"100200","DOI":"10.1016\/j.rechem.2021.100200","article-title":"Review- biological active benzimidazole derivatives","volume":"3","author":"Pathare","year":"2021","journal-title":"Results Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/J.TIV.2019.06.010","article-title":"Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line (AGP01)","volume":"60","author":"Pinto","year":"2019","journal-title":"Toxicol. Vitro"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/J.TIV.2015.08.007","article-title":"The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model","volume":"29","author":"Pinto","year":"2015","journal-title":"Toxicol. Vitro"},{"key":"B31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The role of new tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","article-title":"Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom?","volume":"14","author":"Rosti","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fmolb.2021.628144","article-title":"Drug repurposing strategy (DRS): Emerging approach to identify potential therapeutics for treatment of novel coronavirus infection","volume":"8","author":"Sahoo","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/ACS.JMEDCHEM.8B01040","article-title":"Discovery of Asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1080\/10428194.2017.1312377","article-title":"Treatment of chronic myeloid leukemia: Assessing risk, monitoring response, and optimizing outcome","volume":"58","author":"Shanmuganathan","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"B36","doi-asserted-by":"publisher","first-page":"104125","DOI":"10.1016\/J.BIOORG.2020.104125","article-title":"Novel benzimidazole-triazole hybrids as apoptosis inducing agents in lung cancer: Design, synthesis, 18 F-radiolabeling & galectin-1 inhibition studies","volume":"102","author":"Sridhar Goud","year":"2020","journal-title":"Bioorg. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca. Cancer J. Clin."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1039\/C3MB70577C","article-title":"In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs","volume":"10","author":"Xu","year":"2014","journal-title":"Mol. Biosyst."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.952250\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:31:04Z","timestamp":1661387464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.952250\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":38,"alternative-id":["10.3389\/fphar.2022.952250"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.952250","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"952250"}}